Maria Luisa L. A.
- Country
- Spain
- Department
- Hematology
Research Overview
- Efficacy and Safety of Ianalumab Versus Placebo in Warm Autoimmune Hemolytic Anemia Patients Post-Treatment Failure: A Phase 3 Randomized Double-Blind Study
- Evaluation of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Patients with Autoimmune Cytopenias: An Open-Label Study
- Evaluation of Pozelimab and Cemdisiran Combination Therapy Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naive Paroxysmal Nocturnal Hemoglobinuria Patients
Data & Insights
Has run more than one trial at 56 of 135 partner sites.
Specializations
Thrombocytopenia Research
This investigator specializes in treating primary immune thrombocytopenia (ITP), exploring various therapeutic approaches including combination treatments with romiplostim and dexamethasone. Their work extends to evaluating novel agents like povetacicept for managing autoimmune blood disorders.
- First-line treatment optimization
- Novel therapeutic combinations
- Sustained response assessment
Autoimmune Hematology
The investigator focuses on treating complex autoimmune cytopenias, including warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD). Their research includes innovative treatments using ianalumab and efgartigimod.
- Targeted immunotherapy approaches
- Treatment-resistant cases
- Hemoglobin response monitoring
Emerging Therapeutics
The investigator evaluates new therapeutic agents including HMPL-523 for blood disorders. Their work encompasses assessment of novel compounds' safety profiles and effectiveness in treating various hematologic conditions.
- Drug safety evaluation
- Pharmacokinetic studies
- Treatment response assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.